The drug combination olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a single capsule containing the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.
Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
Olanzapine/fluoxetine is available as a capsule. Currently, five dosage combinations are produced (measured in mg olanzapine/mg fluoxetine): 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg.
Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine and fluoxetine. Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision and difficulty concentrating.
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.
Like other SSRIs, olanzapine/fluoxetine carries a black box warning stating that it could increase the risk of suicide in patients ages 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.
- Symbyax Prescribing Information. Eli Lilly and Company. 2010. http://pi.lilly.com/us/symbyax-pi.pdf
- Grohol, J. "FDA Approves Symbyax for Treatment Resistant Depression." Psych Central. http://psychcentral.com/blog/archives/2009/03/23/fda-approves-symbyax-for-treatment-resistant-depression/
- McIntyre R, Katzman M. (2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders". Bipolar Disord. 5 Suppl 2: 20–35. doi:10.1111/j.1399-2406.2003.00061.x. PMID 14700010.
- Pederson KJ, Roerig JL, Mitchell JE. (2003). "Towards the pharmacotherapy of eating disorders". Expert Opin Pharmacother. 4 (10): 1659–78. doi:10.1517/14656522.214.171.1249. PMID 14521477.CS1 maint: multiple names: authors list (link)
- Koran LM, Ringold AL, Elliott MA. (2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". J Clin Psychiatry. 61 (7): 514–7. doi:10.4088/JCP.v61n0709. PMID 10937610.CS1 maint: multiple names: authors list (link)
- Stein MB, Kline NA, Matloff JL. (2003). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". Am J Psychiatry. 159 (10): 1777–9. doi:10.1176/appi.ajp.159.10.1777. PMID 12359687.CS1 maint: multiple names: authors list (link)
- Drugs.com http://www.drugs.com/pdr/symbyax.html
The following are antidepressant subclasses and drugs
Miscellaneous Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone Template:Serotonergics Template:Dopaminergics Comprehensive list of medications or pharmaceutical drugs used in the United States with their NDC or national drug code, brand name, dosage, forms of administration etc. sorted alphabetically.
List of FDA approved pharmaceutical drugs/medications sorted alphabetically
Comprehensive list of United States Food and Drug Administration approved [[drug]s / [[medication]s sorted alphabetically.